Ray Jordan Joins Moderna as Chief Corporate Affairs Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Ray Jordan has joined Moderna as Chief Corporate Affairs Officer, effective Monday, June 15, 2020. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel.

“It has been a pleasure working with Ray on a consulting basis over the last four months and I am thrilled to welcome him as our Chief Corporate Affairs Officer and to the Executive Committee,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Ray has an impressive track record operating across geographies and at scale at Amgen, J&J and Pfizer. His strategic communications and management experience at global commercial biopharmaceutical companies will be a tremendous asset as we continue into late-stage commercial development of our COVID-19 vaccine and our CMV vaccine.”

Mr. Jordan served as Senior Vice President, Corporate Affairs at Amgen (Nasdaq: AMGN) from 2012 through 2019. At Amgen, he was responsible for all internal and external communications, issues management and philanthropy. During his seven-year tenure, he led strategic communications for an unprecedented six product launches. Prior to Amgen, Mr. Jordan spent nine years at Johnson & Johnson (NYSE: JNJ), where he led corporate communications and public affairs for more than 250 operating companies in 60 countries. Previously, Mr. Jordan held a range of positions over the course of 17 years at Pfizer (NYSE: PFE), most recently as Vice President, Communications and Information. He has also served as chair of PhRMA’s public affairs section and of the National Pharmaceutical Council’s User Group.

“I’ve been keenly interested in Moderna’s mRNA platform and its potential to build a new class of medicine for years. I’ve had the privilege of getting to know the executive committee on a consulting basis over the last four months and I am incredibly impressed with the Moderna team and culture. I look forward to building the corporate affairs team and supporting Moderna’s mission to bring mRNA medicines and vaccines to patients and populations during this exciting time of growth for the company.”

Mr. Jordan received his Master of Business Administration in marketing and finance from Columbia University and his Bachelor of Arts with concentration in psychology and mathematics from Yale University.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).  Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Contacts

Moderna Contacts
Media:
Colleen Hussey

Senior Manager, Corporate Communications

203-470-5620

[email protected]

Investors:
Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]